Interrogating mechanisms of tumor-specific T cell exhaustion and activity in pancreatic ductal adenocarcinoma

C.E. Credits: P.A.C.E. CE Florida CE
Speaker

Abstract

Progress developing immune-based treatments to treat the highly lethal pancreatic ductal adenocarcinoma (PDA) has lagged behind other cancer types. This may be due, in part, to a fibroinflammatory and immunosuppressive tumor microenvironment (TME). To investigate mechanisms of resistance, we developed a novel mouse model to track pancreatic-tumor specific T cells.  While expression of the bioluminescent molecule click beetle red (CB) by tumor epithelial cells permits longitudinal imaging of pancreatic tumor growth in vivo, CB also and unexpectedly generates an immunodominant CD8 T cell epitope (CB101-109:H-2Db) in C57Bl/6 mice. Orthotopic implantation of CB+ PDA cells into syngeneic immunocompetent mice results in the activation, expansion and intratumoral accumulation of CB-specific T cells, thereby modeling the large fraction of PDA cases that have a significant T cell infiltrate. We created a peptide:MHC tetramer to detect CB-specific T cells and demonstrate robust T cell infiltrate. Nonetheless, PDA  induces a state of intratumoral T cell exhaustion characterized by loss of effector functions such as IFN-γ, TNF-α and GzmB and acquisition of regulatory functions such as the production of IL-10. We show that myeloid cells infiltrating PDA produce IL-27, which drives IL-10 production by T cells. Unexpectedly, αCD40 agonist ameliorates intratumoral myeloid cell IL-27 expression and T cell exhaustion, whereas αPD-L1 treatment promotes expansion of splenic CB-specific CD8 T cells. Combination agonistic αCD40 + αPD-L1 resulted in tumor clearance in 63% of animals and generated robust T cell memory. This therapy required IFNγ signaling whereas abrogating TNFα signaling resulted in cures in 100% of treated animals. In sum, this novel PDA animal model provides a tractable and rigorous longitudinal analysis of tumor-specific CD8 T cells which can inform the development of more effective immunotherapy combinations for patient treatment.

Learning Objectives:

1. Identify potential mechanisms driving resistance to immune therapy in pancreatic cancer

2. Appreciate the value of interrogating antigen-specific T cells in the context of disease

3. Elucidate how the tumor microenvironment plays a role in driving T cell exhaustion in malignancy and how combination therapies can operate to interfere with T cell exhaustion


Show Resources
You May Also Like
MAY 11, 2021 10:00 AM PDT
C.E. CREDITS
MAY 11, 2021 10:00 AM PDT
Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
APR 21, 2021 10:00 AM PDT
C.E. CREDITS
APR 21, 2021 10:00 AM PDT
Date: April 21, 2021 Time: 10:00am (PDT), 1:00pm (EDT) Serological testing for SARS-CoV-2 has been steadily adopted into clinical practice over the course of this pandemic. In this webinar,...
FEB 24, 2021 10:00 AM PST
C.E. CREDITS
FEB 24, 2021 10:00 AM PST
DATE: February 24, 2021 TIME: 10am PST Automated lab instruments such as liquid handlers and cell sorters are increasingly common in all types of laboratories, driving fast results for labor...
JUN 09, 2021 7:00 AM PDT
C.E. CREDITS
JUN 09, 2021 7:00 AM PDT
Date: June 9, 2021 Time: 09 June 2021, 7am PDT, 10am EDT, 4pm CEST cells with dramatic implications on the validity of past cell culture related research. The fact that at least 509 cell lin...
JUN 03, 2021 12:00 PM CST
JUN 03, 2021 12:00 PM CST
DATE: June 3, 2021 TIME: 12:00pm SGT This webinar is a virtual event that focuses on utilizing the Gibco CTS Rotea System for Cell and Gene Therapy...
MAR 18, 2021 8:00 AM PDT
C.E. CREDITS
MAR 18, 2021 8:00 AM PDT
DATE: March 18, 2021 TIME: 8:00am PDT Sequencing of bulk cells, single cells, and nuclei is opening doors in the understanding of complex biological processes....
Loading Comments...
Show Resources